STAT1/STAT3 Gain of Function and Mechanisms of Immune Dysregulation by Ayça Kıykım

Subjects: “…janus tyrosine kinase…”
Get full text

Assessment of efficacy and safety of imatinib as an adjunct host-targeted therapy for parasite clearance in chloroquine-resistant malaria: a prospective case control study by Fazeel Zubair Ahmed, Shaifulla P

Subjects: Get full text

Managing novel therapies and concomitant medications in chronic lymphocytic leukemia: key challenges by Sofija Kozarac, Jelena Ivanovic, Marko Mitrovic, Kristina Tomic Vujovic, Isidora Arsenovic, Nada Suvajdzic-Vukovic, Nada Suvajdzic-Vukovic, Andrija Bogdanovic, Andrija Bogdanovic, Ana Vidovic, Ana Vidovic, Milena Todorovic-Balint, Milena Todorovic-Balint, Jelena Bila, Jelena Bila, Mirjana Mitrovic, Mirjana Mitrovic, Danijela Lekovic, Danijela Lekovic, Irena Djunic, Irena Djunic, Marijana Virijevic, Marijana Virijevic, Aleksandar Trivic, Aleksandar Trivic, Jelena Micic, Jelena Micic, Darko Antic, Darko Antic

Subjects: Get full text

RESULTS OF CLINICAL TRIALS OF MEDICAL TREA TMENT OF RENAL CELL CARCINOMA IN 2014–2015 by A. M. Popov, O. B. Karyakin, A. D. Kaprin

Subjects: Get full text

Pediatric and adolescent chronic myeloid leukemia: A follow-up study in Western India by Sangita A. Vanik, Dhaval Jetly, Biren Parikh, Karthik Dhandapani, Rukmini Bezbaruah

Subjects: Get full text

Therapeutic effect of selective interleukin-2-inducible tyrosine kinase inhibitor in orbital fibroblasts from patients with Graves’ orbitopathy by Yeonjung Yoon, Hyun Young Park, Min Kyung Chae, Sun Young Jang, Jin Sook Yoon

Subjects: “…interleukin-2 inducible tyrosine kinase…”
Get full text

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors by Ichiro Yamauchi, Daisuke Yabe

Subjects: Get full text

WALDENSTRÖM MACROGLOBULINEMIA - A STATE-OF-THE-ART REVIEW: PART 1: EPIDEMIOLOGY, PATHOGENESIS, CLINICOPATHOLOGIC CHARACTERISTICS, DIFFERENTIAL DIAGNOSIS, RISK STRATIFICATION, AND C... by Michele Bibas, Shayna Sarosiek, Jorge J. Castillo

Subjects: “…Amyloidosis, Anemia, B cells, BCL2, Bruton tyrosine kinase, Bing-Neel syndrome, Bruton Tyrosine Kinase Inhibitors, Cryoglobulinemia, CXCR4, flow cytometry, hyperviscosity, lymphoplasmacytic lymphoma, MYD88, Waldenström Macroglobulinemia, Peripheral neuropathy.…”
Get full text

Solid lipid nanoparticles for increased oral bioavailability of acalabrutinib in chronic lymphocytic leukaemia by Swagata Sinha, Punna Rao Ravi, Makarand Somvanshi, S. R. Rashmi

Subjects: “…Tyrosine kinase inhibitor…”
Get full text

Association Analysis of Polymorphisms with Aspirin-Exacerbated Respiratory Disease in a Korean Population by Jin Sol Lee, Joon Seol Bae, Byung-Lae Park, Hyun Sub Cheong, Jeong-Hyun Kim, Jason Yongha Kim, Suhg Namgoong, Ji-On Kim, Choon-Sik Park, Hyoung Doo Shin

Subjects: Get full text

Modelling hepatocellular carcinoma microenvironment phenotype to evaluate drug efficacy by Sara Cherradi, Salomé Roux, Marie Dupuy, Séverine Tabone-Eglinger, Edouard Tuaillon, Marianne Ziol, Eric Assenat, Hong Tuan Duong

Subjects: Get full text

Long term efficacy and safety of Lorlatinib in ALK-positive non-small cell lung cancer: A case report by Jialin Qian, Tianqing Chu

Subjects: Get full text

Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Anal... by Ugo Giordano, Agnieszka Piekarska, Witold Prejzner, Lidia Gil, Jan Maciej Zaucha, Joanna Kujawska, Zuzanna Dybko, Krzysztof Dudek, Sebastian Giebel, Jarosław Dybko

Subjects: Get full text

Real‐World Study of EGFR‐TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis o... by Kei Sonehara, Kazunari Tateishi, Kiyotaka Yoh, Kazuhiro Usui, Yukio Hosomi, Kazuma Kishi, Go Naka, Kageaki Watanabe, Shu Tamano, Kohei Uemura, Hideo Kunitoh

Subjects: Get full text

Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial by Xiaoyang Hong, Yongjian Guo, Wenbo Shi, Kangshun Zhu, Licong Liang, Liteng Lin, Ye Chen, Jingwen Zhou, Jingjun Huang, Jiabai Huang, Yaozhu Wu, Wensou Huang, Mingyue Cai

Subjects: Get full text

Comparative safety profile of tyrosine kinase inhibitors in NSCLC: a network meta-analysis of hypertension and thrombotic risks by Mingming Tan, Chenwei Pu, Zhenzhen Wang, Chengwei Jin

Subjects: Get full text

Did selective kinase inhibitors change the management of patients with radioiodine-refractory thyroid cancer? by Tommaso Porcelli, Cristina Luongo, Anna Cerbone, Carmine Di Luccio, Mariantonia Nacchio, Maria Angela De Stefano, Martin Schlumberger, Domenico Salvatore

Subjects: Get full text

The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute... by Xiaoxia Wu, Shenqi Lu, Xinhui Zhang, Zhen Yang, Aining Sun, Depei Wu, Huifen Zhou, Miao Miao

Subjects: Get full text

An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors by Russell J. Schilder, Drew Rasco, Manish R. Sharma

Subjects: Get full text

Rechallenge therapy versus tyrosine kinase inhibitor (TKI) for advanced metastatic colorectal cancer: a retrospective study by Chenming Liu, Jintao Chen, Yuxing Liu

Subjects: “…Tyrosine kinase inhibitor…”
Get full text